HR Execs on the Move

GrayBug

www.graybug.com

 
GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.graybug.com
  • 6411 Beckley St
    Baltimore, MD USA 21224
  • Phone: 443.853.2377

Executives

Name Title Contact Details

Similar Companies

Adventus Group

Adventus Group is a Freeport, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Biotech Medical

Biotech Medical is a Canton, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Omni Environmental Services

Omni Environmental Services is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Feldan Therapeutics

Since its beginning, Feldan has valued internal research with the aim of innovating, changing standards of care and redefining quality of life. With the recent development of the Feldan Shuttle, this approach is starting to show its promises. Feldan`s mission is to develop regenerative medicine therapeutic applications based on Feldan`s proprietary technology.

Peptilogics

Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space, but ensuring that each potential therapeutic is biologically viable and scalable to manufacture. Peptilogics` lead clinical stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need.